CJC-1295
Long-acting GHRH analogue
GHRH analogue that prolongs GH/IGF-1 stimulation.
Back to technical sheets- Class
- Long-acting GHRH analogue
- Also known as
- Studied with or without DAC (drug affinity complex); not approved
Mechanism of action
Analogue of growth-hormone-releasing hormone (GHRH). In its DAC form it binds albumin and prolongs its action, sustaining stimulation of the GH/IGF-1 axis.
Evidence
Early safety and pharmacokinetic studies; no solid efficacy trials. Not approved. Investigational.
Studied uses
- GH/IGF-1 stimulation (research contexts)
Safety considerations
- Sustained IGF-1 elevation with oncologic precautions
- Limited long-term safety data
- Not approved for human use
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Purity
- ≥ 98 % (HPLC)
- Net content
- 80 %
- Batch
- CJC-2601
- Presentation
- Polvo liofilizado en vial sellado
Net content is the fraction of the vial’s weight that is actually peptide, after discounting water, salts and excipients. It is the figure to calculate with, not the label weight.
Sample prices and batch data while the real ones are loaded.
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.